- Home
- MDT vs GILD Comparison
MDT vs GILD Comparison
Compare MDT & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDT
- GILD
- Stock Information
- Founded
- MDT 1949
- GILD 1987
- Country
- MDT Ireland
- GILD United States
- Employees
- MDT N/A
- GILD N/A
- Industry
- MDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDT Health Care
- GILD Health Care
- Exchange
- MDT Nasdaq
- GILD Nasdaq
- Market Cap
- MDT 112.1B
- GILD 129.9B
- IPO Year
- MDT N/A
- GILD 1992
- Fundamental
- Price
- MDT $86.34
- GILD $108.50
- Analyst Decision
- MDT Buy
- GILD Buy
- Analyst Count
- MDT 15
- GILD 25
- Target Price
- MDT $98.00
- GILD $110.17
- AVG Volume (30 Days)
- MDT 8.3M
- GILD 7.9M
- Earning Date
- MDT 05-21-2025
- GILD 08-07-2025
- Dividend Yield
- MDT 3.29%
- GILD 2.93%
- EPS Growth
- MDT 30.80
- GILD 1118.07
- EPS
- MDT 3.61
- GILD 4.73
- Revenue
- MDT $33,537,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- MDT $6.31
- GILD $1.55
- Revenue Next Year
- MDT $5.27
- GILD $3.69
- P/E Ratio
- MDT $23.88
- GILD $22.83
- Revenue Growth
- MDT 3.62
- GILD 4.68
- 52 Week Low
- MDT $75.96
- GILD $64.86
- 52 Week High
- MDT $96.25
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- MDT 52.60
- GILD 50.28
- Support Level
- MDT $85.41
- GILD $107.19
- Resistance Level
- MDT $88.77
- GILD $111.78
- Average True Range (ATR)
- MDT 1.28
- GILD 2.85
- MACD
- MDT 0.01
- GILD -0.43
- Stochastic Oscillator
- MDT 62.96
- GILD 35.89
About MDT Medtronic plc.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).